BETA DRUGS LIMITED Share Price
BETA DRUGS LIMITED Share Price Today
As of 5 Jul 2026, BETA DRUGS LIMITED share price is ₹2,099.00. The stock opened at ₹2,165.20, compared to its previous close of ₹2,155.70. During today's trading session, BETA DRUGS LIMITED share price moved in the range of ₹2,076.70 to ₹2,205.00, with an average price of ₹2,140.85 for the day. Looking at its last 52-week, the stock has touched a low of ₹990.10 and a high of ₹2,250.00. On the performance front, BETA DRUGS LIMITED share price has increased by 28.30% over the last six months and is up 18.91% on a year-on-year basis.
BETA DRUGS LIMITED Returns Calculator
BETA DRUGS LIMITED Shareholder Returns
BETA DRUGS LIMITED Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
BETA DRUGS LIMITED Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹362.36 | ₹295.71 | ₹227.11 | ₹183.84 |
| Other Income | ₹6.44 | ₹1.36 | ₹0.75 | ₹0.76 |
| Total Revenue | ₹368.79 | ₹297.07 | ₹227.87 | ₹184.59 |
| Total Expenses | ₹307.25 | ₹248.32 | ₹186.81 | ₹150.29 |
| Profit Before Tax | ₹56.97 | ₹48.75 | ₹41.06 | ₹34.30 |
| Tax | ₹14.55 | ₹12.32 | ₹10.34 | ₹9.47 |
| Profit After Tax | ₹42.42 | ₹36.44 | ₹30.72 | ₹24.83 |
| EPS - Basic | ₹42.02 | ₹37.90 | ₹31.95 | ₹25.82 |
| EPS - Diluted | ₹42.02 | ₹37.90 | ₹31.95 | ₹25.82 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹61.54 | ₹48.75 | ₹41.06 | ₹34.30 |
| Income before WC changes | ₹55.17 | ₹44.51 | ₹43.08 | ₹39.40 |
| Change in Assets | -₹34.82 | -₹40.71 | -₹28.89 | -₹22.02 |
| Change in Liabilities | ₹15.79 | ₹27.14 | ₹9.19 | ₹12.25 |
| Change in WC | -₹19.03 | -₹13.58 | -₹19.69 | -₹9.77 |
| Cash flow from Operations | ₹36.14 | ₹30.93 | ₹23.38 | ₹29.63 |
| Cash flow from Investing | -₹35.72 | -₹13.97 | -₹19.07 | -₹21.75 |
| Cash flow from Financing | ₹117.97 | -₹7.49 | -₹2.47 | -₹0.97 |
| Total Cash Flow | ₹118.39 | ₹9.47 | ₹1.84 | ₹6.90 |
| Cash (Start of the year) | ₹28.63 | ₹19.16 | ₹17.32 | ₹10.42 |
| Cash (End of the year) | ₹147.02 | ₹28.63 | ₹19.16 | ₹17.32 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹105.16 | ₹76.23 | ₹70.74 | ₹60.89 |
| Current Assets | ₹331.08 | ₹177.87 | ₹127.68 | ₹96.96 |
| Total Assets | ₹436.23 | ₹254.10 | ₹198.42 | ₹157.85 |
| Current Liabilities | ₹102.73 | ₹84.67 | ₹63.02 | ₹48.97 |
| Net Current Asset | ₹228.35 | ₹93.20 | ₹64.67 | ₹47.99 |
| Non-Current Liabilities | ₹136.41 | ₹12.31 | ₹12.52 | ₹16.54 |
| Equity Capital | ₹197.10 | ₹157.12 | ₹122.88 | ₹92.34 |
| Total Equity & Liabilities | ₹436.23 | ₹254.10 | ₹198.42 | ₹157.85 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹220.20 | ₹197.62 | ₹157.87 | ₹124.85 |
| Other Income | ₹6.19 | ₹1.73 | ₹1.04 | ₹0.86 |
| Total Revenue | ₹226.39 | ₹199.35 | ₹158.92 | ₹125.70 |
| Total Expenses | ₹200.98 | ₹169.87 | ₹133.71 | ₹105.54 |
| Profit Before Tax | ₹20.84 | ₹29.48 | ₹25.21 | ₹20.16 |
| Tax | ₹5.41 | ₹7.55 | ₹6.39 | ₹5.92 |
| Profit After Tax | ₹15.43 | ₹21.94 | ₹18.82 | ₹14.25 |
| EPS - Basic | ₹15.29 | ₹22.82 | ₹19.57 | ₹14.82 |
| EPS - Diluted | ₹15.29 | ₹22.82 | ₹19.57 | ₹14.82 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹25.41 | ₹29.48 | ₹25.21 | ₹20.16 |
| Income before WC changes | ₹17.86 | ₹23.19 | ₹25.63 | ₹23.28 |
| Change in Assets | -₹11.85 | -₹19.27 | -₹20.03 | -₹11.89 |
| Change in Liabilities | ₹12.03 | ₹17.26 | ₹4.62 | ₹7.38 |
| Change in WC | ₹0.18 | -₹2.01 | -₹15.41 | -₹4.51 |
| Cash flow from Operations | ₹18.04 | ₹21.19 | ₹10.23 | ₹18.76 |
| Cash flow from Investing | -₹21.46 | -₹11.02 | -₹5.82 | -₹12.72 |
| Cash flow from Financing | ₹118.20 | -₹0.76 | -₹2.19 | ₹1.27 |
| Total Cash Flow | ₹114.79 | ₹9.40 | ₹2.21 | ₹7.31 |
| Cash (Start of the year) | ₹27.20 | ₹17.79 | ₹15.58 | ₹8.27 |
| Cash (End of the year) | ₹141.99 | ₹27.20 | ₹17.79 | ₹15.58 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹76.21 | ₹56.80 | ₹49.04 | ₹48.14 |
| Current Assets | ₹240.31 | ₹113.67 | ₹85.00 | ₹62.76 |
| Total Assets | ₹316.52 | ₹170.47 | ₹134.04 | ₹110.90 |
| Current Liabilities | ₹57.53 | ₹47.66 | ₹31.47 | ₹25.85 |
| Net Current Asset | ₹182.78 | ₹66.01 | ₹53.53 | ₹36.91 |
| Non-Current Liabilities | ₹129.96 | ₹6.80 | ₹6.32 | ₹7.59 |
| Equity Capital | ₹129.04 | ₹116.01 | ₹96.26 | ₹77.46 |
| Total Equity & Liabilities | ₹316.52 | ₹170.47 | ₹134.04 | ₹110.90 |
About BETA DRUGS LIMITED
Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited.
BETA DRUGS LIMITED Financial Highlights
- Revenue: BETA DRUGS LIMITED reported revenue of ₹396.01 crore in FY26 vs ₹368.80 crore in FY25. It showed an increase of 7.38% on a yearly basis.
- Operating Profit: BETA DRUGS LIMITED reported an operating profit of ₹54.39 crore in FY26 vs ₹56.97 crore in FY25. It showed a decrease of 4.53% on a year-on-year basis.
- Net Profit: BETA DRUGS LIMITED reported a net profit of ₹41.48 crore in FY26 vs ₹42.42 crore in FY25. It showed a decrease of 2.22% on a yearly basis.
BETA DRUGS LIMITED Quarterly Result Highlights
- BETA DRUGS LIMITED reported revenue of ₹96.85 crore in Mar 2026, compared with ₹89.58 crore in Dec 2025, representing an increase of 8.12% on a quarter-on-quarter (QoQ) basis.
- BETA DRUGS LIMITED reported an operating profit of ₹11.83 crore in Mar 2026, compared with ₹10.47 crore in Dec 2025, representing an increase of 12.99% on a quarter-on-quarter (QoQ) basis.
- BETA DRUGS LIMITED reported a profit of ₹9.05 crore in Mar 2026, compared with ₹8.52 crore in Dec 2025, reflecting an increase of 6.22% on a QoQ basis.
- The earnings per share (EPS) of BETA DRUGS LIMITED stood at ₹42.02 during Mar 2026.
Similar Stocks
FAQs on BETA DRUGS LIMITED Share Price
What is BETA DRUGS LIMITED share price today?
BETA DRUGS LIMITED share price is ₹2,099.00 as on 03 Jul, 2026, 15:29 IST.
How has the BETA DRUGS LIMITED share price performed in the past?
In the last 1 year, BETA DRUGS LIMITED delivered a return of 18.91%. The BETA DRUGS LIMITED share price hit a high of ₹2,250.00 and low of ₹990.10.
How much is the Mutual Fund shareholding in BETA DRUGS LIMITED shares?
The Mutual Fund Shareholding in BETA DRUGS LIMITED was 0.00% at the end of May 2026.
What is the the 52-week high and low of BETA DRUGS LIMITED shares ?
The 52-week high and low of BETA DRUGS LIMITED share is ₹2,250.00 and ₹990.10 as of 03 Jul, 2026.
What is the market cap of BETA DRUGS LIMITED?
The market capitalisation of BETA DRUGS LIMITED is ₹2,185.21 Crores as on 03 Jul, 2026.
What are the stock symbols of BETA DRUGS LIMITED?
The stock symbol of BETA DRUGS LIMITED is BETA on the NSE, , and the ISIN is INE351Y01019.
What was yesterday's closing price for BETA DRUGS LIMITED shares ?
BETA DRUGS LIMITED shares closed yesterday at ₹2,155.70 on NSE
How to buy BETA DRUGS LIMITED shares?
To buy BETA DRUGS LIMITED shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy BETA DRUGS LIMITED shares on Holidays?
No, shares of BETA DRUGS LIMITED or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell BETA DRUGS LIMITED shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of BETA DRUGS LIMITED?
The PE and PB ratio of BETA DRUGS LIMITED is 52.68 and 8.93 respectively, as on 03 Jul, 2026, 15:29 IST.